Aanchal Ispat Limited is seeking shareholder approval to issue 10.55 lakh warrants to its promoter, Mukesh Goel, for ₹8.65 crore. The funds will primarily be used to meet NCLT-approved Resolution Plan obligations.
Aanchal Ispat Ltd to Issue Warrants to Promoter
10,55,000 warrants to be issued at ₹82 each.
Total consideration: ₹8.65 crore.
Reader Takeaway: Promoter confidence boosts revival plan; NCLT obligations funding is key pressure point.
What just happened
Aanchal Ispat Limited has announced its intention to issue 10,55,000 fully convertible warrants on a preferential basis to its promoter, Mr. Mukesh Goel. This move requires shareholder approval at an upcoming Extra-Ordinary General Meeting (EGM).
The total consideration for these warrants is ₹8.65 crore. The issue price is fixed at ₹82 per warrant, comprising a face value of ₹10 and a premium of ₹72. The proceeds will be used primarily to meet payment obligations under the company's NCLT-approved Resolution Plan, with ₹8.53 crore allocated for this purpose, and ₹0.12 crore for allotment expenses.
Why this matters
This preferential issue is a crucial step for Aanchal Ispat as it is currently undergoing a revival phase after being admitted into the Corporate Insolvency Resolution Process (CIRP) in September 2023. The National Company Law Tribunal (NCLT) approved the resolution plan on March 27, 2025. The funds raised are intended to facilitate the implementation of this plan by settling stakeholders' dues and restructuring the company's capital.
This action also signals promoter confidence, with Mr. Mukesh Goel's holding expected to increase from 50.20% to 60.13% post-issue. Investors will be looking at how this capital infusion helps stabilize the company's financial position.
The backstory
The company was admitted into CIRP in September 2023. The NCLT approval of the resolution plan on March 27, 2025, marked a significant turning point. This preferential issue is a direct follow-up to operationalize that approved plan.
What changes now
Shareholder approval at the EGM, scheduled for July 23, 2026, will greenlight the capital infusion. The promoter's stake will increase, reflecting a stronger promoter commitment. The company will gain the necessary funds to proceed with debt settlement as per the NCLT plan.
Risks to watch
Investors should be aware that 25% of the issue price is payable upfront. If the warrants are not converted into equity shares within the 18-month exercise period from allotment, this upfront payment will be forfeited. The funding requirements are based on internal estimates and have not been independently appraised.
Peer comparison
Information on peer comparison is not available in the filing.
Context metrics (time-bound)
- CIRP Admission: September 2023
- NCLT Resolution Plan Approval: March 27, 2025
- EGM for Shareholder Approval: July 23, 2026
- Warrant Conversion Period: Within 18 months from allotment
What to track next
Investors should closely monitor the outcome of the EGM vote on July 23, 2026. Additionally, tracking the timely deployment of the raised funds towards settling obligations under the NCLT-approved Resolution Plan will be critical.